Volume 65, Issue 3, Pages (September 2016)

Slides:



Advertisements
Similar presentations
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Advertisements

Omega 3 – Omega 6: What is right for the liver? Ashraf Mohammad El-Badry, Rolf Graf, Pierre-Alain Clavien Journal of Hepatology Volume 47, Issue 5, Pages.
Volume 61, Issue 2, Pages (August 2014)
Volume 63, Issue 1, Pages (July 2015)
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 46, Issue 3, Pages (March 2007)
Volume 41, Issue 6, Pages (December 2004)
Volume 67, Issue 3, Pages (September 2017)
Kirsten Boonstra, Ulrich Beuers, Cyriel Y. Ponsioen 
Inflammasomes in liver diseases
Volume 67, Issue 3, Pages (September 2017)
MELD: the holy grail of organ allocation?
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: A systematic review  Christian Thoma, Christopher P. Day, Michael.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Reproducibility of Liver Stiffness Measurement by Ultrasonographic Elastometry  Jérôme Boursier, Anselme Konaté, Gabriella Gorea, Stéphane Reaud, Emmanuel.
Flavia D. Mendes, Ayako Suzuki, Schuyler O. Sanderson, Keith D
Volume 42, Issue 6, Pages (June 2005)
Halis Simsek, Ali Shorbagi, Yasemin Balaban, Gonca Tatar 
Matthew T. Kitson, Stuart K. Roberts  Journal of Hepatology 
Volume 128, Issue 2, Pages (February 2005)
Non-invasive diagnosis of non-alcoholic fatty liver disease
Volume 64, Issue 3, Pages (March 2016)
Individualized prediction of hepatocellular carcinoma occurrence in a large cohort of patients with cirrhosis  Astrid Marot, Jean Henrion, Jean-François.
Living donor liver transplantation: is the hype over?
Volume 42, Issue 4, Pages (April 2005)
Reply to: “DCD consensus and futility in liver transplantation”
Volume 44, Pages S19-S24 (January 2006)
Stephen A. Harrison, MD, FACP  Clinical Gastroenterology and Hepatology 
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
Figure 1. Table for calculating the accuracy of a diagnostic test.
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
Mauro Bernardi, Stefano Gitto, Maurizio Biselli  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Volume 68, Issue 1, Pages (January 2018)
Hepatitis C core protein – The “core” of immune deception?
Vincent Leroy, Jean-Pierre Zarski  Journal of Hepatology 
Volume 140, Issue 7, Pages e3 (June 2011)
Marc van der Valk, Hans L. Zaaijer, Arnon P. Kater, Janke Schinkel 
Volume 44, Issue 1, Pages (January 2006)
Statin use and the risk of hepatocellular carcinoma in patients at high risk: A nationwide nested case-control study  Gyuri Kim, Suk-Yong Jang, Chung.
Trends in the management and burden of alcoholic liver disease
Volume 54, Issue 5, Pages (May 2011)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Volume 62, Issue 3, Pages (March 2015)
Volume 69, Issue 4, Pages (October 2018)
EASL Clinical Practice Guidelines: Wilson’s disease
Roberto de Franchis, Aleksander Krag  Journal of Hepatology 
Julie Parkes, Indra Neil Guha, Paul Roderick, William Rosenberg 
Volume 41, Issue 4, Pages (October 2004)
The changing role of beta-blocker therapy in patients with cirrhosis
Volume 57, Issue 5, Pages (November 2012)
Volume 69, Issue 5, Pages (November 2018)
Paul C. Adams, James C. Barton  Journal of Hepatology 
Volume 50, Issue 3, Pages (March 2009)
Volume 67, Issue 3, Pages (September 2017)
Global burden of alcoholic liver diseases
Volume 64, Issue 6, Pages (June 2016)
The impact of intestinal microflora on serum bilirubin levels
Volume 63, Issue 1, Pages (July 2015)
Volume 66, Issue 3, Pages (March 2017)
Volume 62, Issue 3, Pages (March 2015)
New trials and results in systemic treatment of HCC
Liver transplantation in children
Pathogenesis of cholestatic hepatitis C
Volume 50, Issue 1, Pages 4-6 (January 2009)
Volume 64, Issue 2, Pages (February 2016)
MELD: the holy grail of organ allocation?
Thierry Gustot, Rajiv Jalan  Journal of Hepatology 
Volume 70, Issue 5, Pages (May 2019)
Presentation transcript:

Volume 65, Issue 3, Pages 570-578 (September 2016) Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver disease  Jérôme Boursier, Julien Vergniol, Anne Guillet, Jean-Baptiste Hiriart, Adrien Lannes, Brigitte Le Bail, Sophie Michalak, Faiza Chermak, Sandrine Bertrais, Juliette Foucher, Frédéric Oberti, Maude Charbonnier, Isabelle Fouchard-Hubert, Marie-Christine Rousselet, Paul Calès, Victor de Lédinghen  Journal of Hepatology  Volume 65, Issue 3, Pages 570-578 (September 2016) DOI: 10.1016/j.jhep.2016.04.023 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Rate of patients included in the intervals of ⩾90% negative (NPV) or positive (PPV) predictive values, as a function of blood fibrosis tests or liver stiffness measurement by FibroScan (LSM). The patients in the ‘grey zone’ are those for whom NPV and PPV are <90%. Results presented are those obtained in the core group allowing for direct comparisons between fibrosis tests. NFS, NAFLD Fibrosis Score; FMNAFLD, FibroMeterNAFLD; FMV2G, FibroMeterV2G. Journal of Hepatology 2016 65, 570-578DOI: (10.1016/j.jhep.2016.04.023) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Fibrosis classifications of FibroScan and FibroMeterV2G which give an estimation of the pathological fibrosis stage from the fibrosis test result. LSM, liver stiffness measurement by FibroScan. (This figure appears in colour on the web.) Journal of Hepatology 2016 65, 570-578DOI: (10.1016/j.jhep.2016.04.023) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Overall survival as a function of the subgroups defined by (A) the fibrosis classification developed for liver stiffness measurement by Fibroscan (LSM) or (B) the fibrosis classification developed for FibroMeterV2G. (This figure appears in colour on the web.) Journal of Hepatology 2016 65, 570-578DOI: (10.1016/j.jhep.2016.04.023) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Simplified fibrosis classifications for LSM and FibroMeterV2G. These classifications stratify NAFLD patients into four subgroups with significantly different prognoses. (This figure appears in colour on the web.) Journal of Hepatology 2016 65, 570-578DOI: (10.1016/j.jhep.2016.04.023) Copyright © 2016 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2016 65, 570-578DOI: (10. 1016/j. jhep. 2016. 04 Copyright © 2016 European Association for the Study of the Liver Terms and Conditions